Key result
TigerPaw Pro achieves 100% complete appendage closure with zero procedural adverse events in preclinical testing.
Why the study?
Left atrial appendage occlusion is an alternative to anticoagulation in atrial fibrillation, but the usability, safety, and efficacy of a novel epicardial device require evaluation.
Does the TigerPaw Pro device provide safe and effective epicardial left atrial appendage occlusion in a canine model?
Does the TigerPaw Pro device provide safe and effective epicardial left atrial appendage occlusion in a canine model?
The TigerPaw Pro device demonstrated procedural feasibility, safety, and efficacy for epicardial left atrial appendage occlusion in a preclinical canine model.
Answers are grounded in this paper and cite their sources.
Supports preclinical feasibility of TPP for epicardial LAAO; leaves open translation to human AF patients pending clinical trials.
BACKGROUND: Left atrial appendage occlusion (LAAO) represents a treatment alternative to anticoagulation in patients with atrial fibrillation. We evaluate a novel device for epicardial LAAO in a translational canine model. METHODS: Nine hounds (n = 9) were used to assess usability, safety, and efficacy of the TigerPaw Pro (TPP) device for epicardial LAAO. Following baseline imaging (intra-cardiac echocardiography (ICE) and angiography) and intraoperative visual inspection, usability was tested via a ``closure/re-opening`` maneuver followed by deployment of a total of twenty TPP devices (n = 20) on the left and right atrial appendages respectively. Procedural safety was evaluated by assessing for adverse-events via direct Epicardial inspection and endocardial imaging. Efficacy evaluation included assessment of device positioning, presence of residual stumps and completeness of closure. Post-mortem evaluation was performed to confirm safety and efficacy. RESULTS: Usability testing of all TPP devices was successful (n = 20;100%, delivery-time range 22-120 s) without any procedural adverse-events (tissue damage or tears, bleeding, vessel-impingement, structural impact). All devices fully traversed the ostium (n = 18) or appendage body (n = 2), and conformed smoothly to adjacent cardiac anatomy. In nineteen deployments (n = 19;95%), all device connector pairs were fully engaged, while in one TPP device the most distal pair remained unengaged. ICE and post-mortem inspections revealed complete closure of all appendage ostia (n = 18;100%) and only in one case a small residual stump was detected. Intraoperative safety findings were further confirmed post-mortem. Devices created a nearly smooth line of closure via symmetric endocardial tissue-coaptation. CONCLUSIONS: In this preclinical model, the TPP demonstrated good ease of use for ostial access, ability to re-position (after engagement) and rapid deployment, while achieving safe and effective LAAO.
No takes yet. Share an insight, caveat, or question.
Emmert et al. (2020) studied Atrial fibrillation (translational model) (n=9). TigerPaw Pro (TPP) device was evaluated on Complete closure of appendage ostia. The TigerPaw Pro device achieved 100% successful deployment and complete appendage closure without procedural adverse events in a preclinical canine model.
Synapse has enriched 10 related papers. Consider them for comparative context: